You are here:
The main research area of Harm Peter's group "molecular fibrosis research" concentrates on new aspects in the pathogenesis and treatment of acute and chronic fibrotic diseases of the kidney and their consequences for the cardiovascular system. With regard to the kidney, the research group compares immune-mediated (acute anti-Thy1 glomerulonephritis, lupus nephritis) with not primarily inflammatory disease models (5/6 nephrectomy, diabetic nephropathy).
In addition, kidney transplant models are analyzed. With regard to the vascular consequences of impaired renal function, the research focus is on changes of the myocard, coronary arteries and large vessels. In order to unravel the underlying mechanism of pathological changes, the group concentrates on cellular mediators such as mast cells, lymphocytes (S1P modulation by FTY720) und platelets (inhibition by clopidogrel) and several extra- and intracellular pathways. These include transforming growth factor beta (small molecule inhibition), PDGF (receptor blockade with imatinib), mammalian target of rapamycin (mTOR-inhibitor sirolimus), NO/cGMP signal transduction (stimulator of soluble guanylate cyclase BAY 41-2272) and the renin-angiotensin-systems (maximizing RAS inhibition and AT2 receptor stimulation). In the following, you will find an overview on the scientific questions and projects approached from 2006 until today.